A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
Study Details
Medical Condition
Study Phase
Intervention Type
Date
Participation Requirements
Gender
Age
Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Have a question?
You can ask us questions via online form or phone call.
Call us @: 844 663-3742
| Location | Status | Site Contact Details |
|---|---|---|
Location Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev, Kemerovo, Kemerovskaya Oblast, 650066 | Status Not Available | |
Location Clinical Hospital No.1 n.a. N.I.Pirogov, Moscow, Moskva, 119049 | Status Not Available | |
Location Ivanovo Regional Clinical Hosp, Ivanovo, 153040 | Status Not Available | |
Location Institution KhMAO-Ugra, Khanty-mansiysk, 628011 | Status Not Available | |
Location State Clinical policlinic, Moscow, 107023 | Status Not Available | |
Location Central Research Institute, Moscow, 111123 | Status Not Available | |
Location Research Institute of Rheum, Moscow, 115522 | Status Not Available | |
Location Advisory-diagnostic Hospital, Moscow, 117041 | Status Not Available | |
Location State Clinical Hospital, Moscow, 119049 | Status Not Available | |
Location GBUZ Republican Hospital, Petrozavodsk, 185019 | Status Not Available | |
Location Smolensk station JSC Russian R, Smolensk, 214025 | Status Not Available | |
Location Nort-Western State Medical Uni, St. Petersburg, 191015 | Status Not Available | |
Location Tula Regional Clinical Hospita, Tula, 300053 | Status Not Available | |
Location Yaroslavi State Medical Univer, Yaroslavl, 150000 | Status Not Available |
The objective of this study is to access retention rate, persistence and adherence in population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis (PsA)) participants treated with adalimumab in routine clinical settings in the Russian Federation.
Proportion of participants on adalimumab therapy
Time Frame: Up to 30 days after administering last dose in the study (52 weeks)
Number of participants on adalimumab therapy
Time Frame: Up to 30 days after administering last dose in the study (52 weeks)
Assessing medication persistence
Time Frame: Up to 48 weeks of treatment period
Assessing medication adherence
Time Frame: Up to 48 weeks of treatment period
Change of disease activity in participants with PsA
Time Frame: Up to 48 weeks of treatment period
Change of disease activity in participants with AS
Time Frame: Up to 48 weeks of treatment period
Interventions:
- Not Available
Enrollment:
139
Available Documents
FaFilePdfScientific Result Summary (English)Additional Information
Watch a video to learn more about what you may experience as a clinical trial volunteer: /resources/what-happens-in-a-clinical-trial
Take a virtual reality screening visit tour to an example of a clinical trial site: /resources/screening-visit-virtual-tour
Use a questionnaire tool to think through questions to ask yourself about participating in a clinical trial and print out your responses to discuss with your partners in your health journey: /resource-information-clinical-trial-community/decision-counselor